|
Published by: Fuji-Keizai USA, Inc.
Published: Mar. 1, 2002 - 126 Pages
Table of Contents
1 Overview of the Bio-Tools Market for Drug Discovery
1.1 The Bio-Tools Market Landscape (Companies)
1.1.2 Hardware Vendors
1.1.3 Genomics Companies
1.1.4 Proteomics Companies
1.1.5 Bioinformatics Software Companies
1.1.6 BioDatabase Companies
1.1.7 Drug Discovery Companies (Target Identification and Validation)
1.1.8 Emerging Technology Companies
1.1.9 Reagent and Consumables Vendors
1.2 Overview of Next Generation Bio-Tool Developments for Drug Discovery
1.2.1 Gene Sequencing Systems
1.2.2 Protein Separation Tools
1.2.3 Mass Spectrometers (MS)
1.2.4 Hybridization Arrays
1.2.5 Emerging Technologies
1.2.6 Bioinformatics/Chemoinformatics
1.3 Next Generation Bio-Tool Applications for R&D
1.3.1 Biopharmaceutical Drug Discovery
1.3.2 R&D Diagnostic Tools
1.3.3 Agricultural and Veterinary Applications
2 Drivers for Next Gen Bio-Tools Developments
2.1 Global Market Opportunity to Make Multi-Billion Dollar Revenues
2.2 Growing Pace of Pharmaceutical Mergers and Acqusitions
2.2.1 Rapid Pace of Scientific Developments
2.2.2 Cost and Time-to-Market Considerations
2.3 Drug Discovery R&D
2.3.2 Creation of Post Genomic Era R&D Databases
2.3.3 Proteomics R&D Requres More New Tools
3 Strategies for Next Generation Bio-Tools for R&D
3.1 Business Model and Intellectual Property
3.1.1 Business Model
3.1.2 Intellectual Property (IP)
3.2 How They Make Money
3.2.1 Technology Platform Out-Licensing.
3.2.2 Producing and Selling Comsumable Products for R&D
3.2.3 Produce and Sell Equipment Platforms to R&D Customers
3.2.4 Become a Biotech Drug Discovery Company
3.3 Strategic Goals
3.3.1 Establish Customer Base with Largest Pharmas
3.3.2 Make Key Alliances or Partnerships
3.3.3 Grow the Company to Make Critical Mass
3.4 Business Development Strategies
3.4.1 Traditional Partnering
3.4.2 Become a Technology Roll-up
3.4.3 Merge with Another Biotech
4 The Market Forecast for Next Generation Bio-Tools
4.1 The Next Gen. Bio-Tools for the Drug Discovery R&D Market
4.2 Next Gen. Bio-Tools R&D Market Size by Segment, 2000~2005
4.3 Industry Segments and NG Bio-Tools Companies
4.3.1 Target Identification Genomic Technologies
4.3.2 Target Identification Protein Technologies
4.3.3 Protein Chip
4.3.4 Protein Databases
4.3.5 Target Validation
4.3.6 Drug Lead Screening
4.3.7 Preclinical Development
4.3.8 Phase 1-3 Clinical Development & Diagnostics
5 Activities of the Firms Making Next Generation Bio-Tools for R&D
5.1 Bioinformatics Databases
5.1.1 Celera Genomics Corporation
5.1.2 Incyte Genomics, Inc.
5.2 Bioinformatics Tools
5.2.1 Accelrys, Inc.
5.2.2 InforMax, Inc.
5.2.3 Spotfire, Inc.
5.2.4 Xanthon, Inc.
5.3 Drug Discovery Tools
5.3.1 ACLARA BioSciences, Inc.
5.3.2 Ciphergen Biosystems, Inc.
5.3.3 GeneMachines, Inc.
5.4 Emerging Technologies
5.4.1 Affymetrix, Inc.
5.4.2 Gene Logic, Inc.
5.4.3 Illumina, Inc.
5.4.4 Nanogen, Inc.
5.4.5 Zyomyx, Inc.
5.5 Reagents and Consumables
5.5.1 Cepheid
5.5.2 Molecular Staging, Inc.
5.5.3 Phylos, Inc.
6 Future Directions in Next Generation Bio-Tools for R&D
6.1 Future Directions in Bio-Tools R&D
6.2 Review of Past Trends
6.2.1 Recent Developments in Genomics That Impact on Bio-Tools
6.3 Indicators of Future Trends for NG Bio-Tools for R&D
6.3.1 Strong Financing for Bio-tools Companies
6.3.2 Biotechnology Conferences
6.3.3 University Labs at Work
6.3.4 Bioinformatics Software.
6.3.5 Bioinformatics Databases
6.3.6 Emerging Protein Technology
6.3.7 Nanobiotechnology is Emerging
7 Conclusions and New Opportunities
7.1 Likely Bio-Tools Success and Failure Factors
7.2 Highlights of Hot Development Areas of Bio-Tools
7.3 Next Generation Bio-Tools Opportunities
7.3.1 Bio-tools for Faster, Better, Cheaper R&D
7.3.2 Industrial Scale Proteomics
7.3.3 Goal of Personalized Medicine
7.4 Summary
8 Appendix
8.1 Bioscience Glossary
List of Tables
Table 1. Estimated Total NG BioTools Market Size by Segment Revenues
Table 2. Total NG Bio-Tools Market Segments by Percent Market Share
Table 3. NG Drug Discovery Tools Segment by Revenues
Table 4. NG Bioinformatics Tools Segment by Revenues
Table 5. NG Reagents and Consumable Bio-Tools Segment by Revenues
Table 6. NG Emerging Technologies Segment by Revenues
Table 7. Leading NG Drug Discovery Tools Companies
Table 8. Leading NG Bioinformatics Tools Companies
Table 9. Leading NG Reagents & Consumables Companies
Table 10. Leading Emerging Technologies Companies
Table 11. Leading NG Drug Discovery Companies
Table 12. Future Directions of Next Generation Bio-Tools for R&D
List of Figures
Figure 1. Next Generation Bio-Tools Vendor Market
Figure 2. Drug R&D Summary
Figure 3. Liquid Handling Systems
Figure 4. Incyte’s Protein Expression Analysis Software
Figure 5. ScreenMate Products for HTS in Drug Lead R&D
Figure 6. Rolling Circle Amplification Technology (RCAT)
Figure 7. The InforMax ProChart™ Database for Protein Visualization
Figure 8. Computer Model using PhysioLab Technology
Figure 9. Big Pharma and Big Biotech Drug R&D Timeline
Figure 10. Using Parallel Processes to Increase Drug Discovery Productivity
Figure 11. Estimated Total NG BioTools Market Size by Revenues
Figure 12. Estimated Total NG Bio-Tools Market Size by Segment Revenues, 2000-2005
Figure 13. Comparison of Estimated Total NG Bio-Tools Market Size by Segment Revenues, 2000-2005
Figure 14. Comparison of Segment Market Shares for the NG Bio-Tools Market, 2001 and 2005
Figure 15. NG Drug Discovery Tools Segment by Revenues
Figure 16. NG Bioinformatics Tools Segment by Revenues
Figure 17. NG Reagents and Consumable Bio-Tools Segment by Revenues
Figure 18. NG Emerging Technologies Segment by Revenues
Figure 19. Agilent ProteinChip
Figure 20. The SpotFire DecisionSite User Interface
Figure 21. Accelrys GCG Wisconsin Package - SeqLab
Figure 22. The Incyte/ Oxford Glycoscience Proteome Analysis Process
Figure 23. Next Generation Bio-Tools Opportunity Map
AbstractThis report is new research about the technologies, opportunities and the market for next generation bio-tools that are being used for accelerating the research processes and capabilities of bio-pharmaceutical drug discovery. Next generation bio-tools market is the emerging and smaller subset of the bio-tools market. This study has found that the total next generation bio-tools market size in 2001 is about $1.4 billion and is projected to double to about $2.9 billion in 2005 with a CAGR of 23.7%.
This report has found that the big pharma industry generated about $250 billion in 2001 and is facing many important issues that could be helped with next generation bio-tools. Pharma companies have seen their R&D costs explode as their delivery of new drug products have declined. Many of their high priced $billion+ blockbuster drugs will reach their patent expirey dates by 2005-2006 and draw competition from generic drug makers. These companies have tried growing through M&As, but their growth has not increased.
As a result, pharma companies have increasingly become a source of strong financial and research partners with many of the companies that comprise about 1360 companies that make up the biotechnology industry. Pharma companies are motivated to become customers and partners of bio-tools companies because the many “tools” companies have technologies that might help the big pharma companies become more productive and deliver more than one product, in a shortened time frame rather than in the current 10-15 year drug development process.
Accelerating the drug making process means turning to modern industrialization of R&D, using genomics and proteomics technologies, and other that bio-tools companies can provide. The report discusses are these important issues with interesting and useful findings. This study uses more than 20 figures and tables to illustrate the findings.
Get Full Details About This Report >>
|
